Mouse Anti-HORMAD1 (AA 1-395) Recombinant Antibody (CBFYH-1716) (CBMAB-H0653-FY)

Okutman, O., Boivin, M., Muller, J., Charlet-Berguerand, N., & Viville, S. (2023). A biallelic loss of function variant in HORMAD1 within a large consanguineous Turkish family is associated with spermatogenic arrest. Human Reproduction, 38(2), 306-314.

Tarantino, D., Walker, C., Weekes, D., Pemberton, H., Davidson, K., Torga, G., ... & NJ Tutt, A. (2022). Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance. Oncogene, 41(32), 3969-3977.

Liu, K., Cheng, L., Zhu, K., Wang, J., & Shu, Q. (2022). The cancer/testis antigen HORMAD1 mediates epithelial–mesenchymal transition to promote tumor growth and metastasis by activating the Wnt/β-catenin signaling pathway in lung cancer. Cell Death Discovery, 8(1), 136.

Zong, B., Sun, L., Peng, Y., Wang, Y., Yu, Y., Lei, J., ... & Liu, S. (2021). HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance Corrigendum in/10.3892/or. 2021.8146. Oncology reports, 46(1), 1-15.

Liu, K., Wang, Y., Zhu, Q., Li, P., Chen, J., Tang, Z., ... & Liu, Y. (2020). Aberrantly expressed HORMAD1 disrupts nuclear localization of MCM8–MCM9 complex and compromises DNA mismatch repair in cancer cells. Cell death & disease, 11(7), 519.

Fujiwara, Y., Horisawa-Takada, Y., Inoue, E., Tani, N., Shibuya, H., Fujimura, S., ... & Ishiguro, K. I. (2020). Meiotic cohesins mediate initial loading of HORMAD1 to the chromosomes and coordinate SC formation during meiotic prophase. PLoS genetics, 16(9), e1009048.

Carofiglio, F., Sleddens-Linkels, E., Wassenaar, E., Inagaki, A., van Cappellen, W. A., Grootegoed, J. A., ... & Baarends, W. M. (2018). Repair of exogenous DNA double-strand breaks promotes chromosome synapsis in SPO11-mutant mouse meiocytes, and is altered in the absence of HORMAD1. DNA repair, 63, 25-38.

Nichols, B. A., Oswald, N. W., McMillan, E. A., McGlynn, K., Yan, J., Kim, M. S., ... & Whitehurst, A. W. (2018). HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress. Cancer research, 78(21), 6196-6208.

Gao, Y., Kardos, J., Yang, Y., Tamir, T. Y., Mutter-Rottmayer, E., Weissman, B., ... & Vaziri, C. (2018). The cancer/testes (CT) antigen HORMAD1 promotes homologous recombinational DNA repair and radioresistance in lung adenocarcinoma cells. Scientific reports, 8(1), 15304.

Wang, X., Tan, Y., Cao, X., Kim, J. A., Chen, T., Hu, Y., ... & Wang, X. (2018). Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity. Oncotarget, 9(53), 30115.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols